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Mitochondrial dysfunction is a prominent feature of various neurodegenerative diseases as strict regulation of integrated
mitochondrial functions is essential for neuronal signaling, plasticity, and transmitter release. Many lines of evidence
suggest that mitochondrial dysfunction plays a central role in the pathogenesis of Parkinson’s disease (PD). Several PD-
associated genes interface with mitochondrial dynamics regulating the structure and function of the mitochondrial network.
Mitochondrial dysfunction can induce neuron death through a plethora of mechanisms. Both mitochondrial dysfunction and
neuroinﬂammation, a common denominator of PD, lead to an increased production of reactive oxygen species, which are
detrimental to neurons. The transcription factor nuclear factor E2-related factor 2 (Nrf2, NFE2L2) is an emerging target to
counteract mitochondrial dysfunction and its consequences in PD. Nrf2 activates the antioxidant response element (ARE)
pathway, including a battery of cytoprotective genes such as antioxidants and anti-inﬂammatory genes and several transcription
factors involved in mitochondrial biogenesis. Here, the current knowledge about the role of mitochondrial dysfunction in PD,
Nrf2/ARE stress-response mechanisms, and the evidence for speciﬁc links between this pathway and PD are summarized. The
neuroprotection of nigral dopaminergic neurons by the activation of Nrf2 through several inducers in PD is also emphasized as a
promising therapeutic approach.
1.Introduction
Parkinson’s disease (PD) is a prevalent and progressive neu-
rodegenerative incurable movement disorder. The disease is
characterized by the loss of dopaminergic neurons in the
substantia nigra pars compacta (SNpc) and the presence
of proteinaceous deposits within neuronal perikarya (Lewy
bodies) and processes (Lewy neurites). These deposits are
composed of α-synuclein, ubiquitin, neuroﬁlaments, and
molecular chaperones [1]. Nigral dopaminergic neuron
deathleads toa deﬁciencyofthe neurotransmitter dopamine
inthestriatumandconsequentdysregulation ofbasalganglia
circuitries accounting for motor symptoms of bradykinesia,
hypokinesia, progressive rigidity, resting tremor, and postu-
ral instability. Lewy body deposition is also associated with
nonmotor features such as autonomic dysfunction, sleep
disturbances, depression, and cognitive impairment [1, 2].
A major risk factor is aging, as in other neurodegenerative
diseases, although people with the familial monogenic forms
of the disease can present before 45 years of age [1].
Since the sporadic and monogenic forms of PD share
important clinical, pathological, and biochemical features,
notably the progressive demise of dopaminergic neurons in
the substantia nigra (SN), inherited mutations underlying
familial forms have provided insight into the molecular
mechanisms of disease pathogenesis [1, 3]. Oxidative stress,
neuroinﬂammation, mitochondrial dysfunction, aberrant
protein aggregation, excitotoxicity, and alterations in the
autophagic-lysosomal pathway are implicated in the devel-
opment and progression of PD [4–6]. PD also seems to have
a mitochondrial component, so events that would modulate
normal mitochondrial functions may compromise neuronal
survival.
Nuclear factor E2-related factor 2 (Nrf2, NFE2L2) is a
master regulator that induces a battery of cytoprotective
genes including antioxidative enzymes, anti-inﬂammatory2 Parkinson’s Disease
mediators, the proteasome, and several transcription factors
involved in mitochondrial biogenesis. Thus, it may be a
promising target to counteract mitochondrial dysfunction
and its consequences in PD. Following its nuclear transloca-
tion, Nrf2 binds the antioxidant response elements (AREs)
in the promoter region of its target genes. Several lines of
evidence including in vivo Nrf2-deﬁcient mouse studies,
postmortem studies of PD brains, and genetic association
studiesofpatientsindicatea linkbetweenNrf2 dysregulation
and PD pathogenesis. Endogenous responses to upregulate
Nrf2 and mitochondrial biogenesis in PD may be insuﬃcient
to prevent the progression of neurodegeneration. Thus,
further activation of the Nrf2/ARE system using exogenous
inducers may be a plausible therapeutic approach for PD.
This paper provides a brief overview of mitochon-
drial dynamics, mitochondrial dysfunction in PD, and the
Nrf2/ARE system. In addition, recent studies indicating a
link between Nrf2 and PD are summarized. Finally, recent
eﬀorts employing inducers of Nrf2 activity to provide
neuroprotection of nigral dopaminergic neurons in PD are
emphasized.
2.The Functions,Biogenesis, and
Dysfunctionof Mitochondria
Mitochondria are membrane-enclosed organelles, which
uniquely contain genetic material independent of nuclear
DNA. These 1–10μm long cellular structures contain their
own genome, which encodes tRNAs, rRNAs and 13 mito-
chondrial proteins [7, 8], while other components of the
mitochondrial respiratory chain are encoded by the nuclear
genome [9]. Multiple copies of the circular DNA are present
in each mitochondrion. In humans, the size of the mito-
chondrial genome is 16,569bp and encodes for 2 ribosomal
RNA molecules (16S and 12S rRNA) and 22 transfer RNA
molecules [9, 10].
The structure of a mitochondrion includes outer mem-
brane, intermembrane space, inner membrane, and matrix
[8]. The topography of the inner membrane is complex
and includes the electron transport system complexes, the
adenosine triphosphate (ATP) synthetase complex, and
transport proteins [11]. Mitochondria produce most of
the cell’s energy in the form of ATP through oxidative
phosphorylation (OXPHOS). Depending on this process,
there are ﬁve intramembrane complexes and two mobile
electron carriers, called coenzyme Q and cytochrome c
[12]. Cytochrome c, which is an essential component of
the electron transport chain, is located in the outer face
o ft h ei n n e rm e m b r a n e( i n t e r m e m b r a n es p a c e )o ft h e
mitochondrion [13]. Cristae are structures that are formed
by the folding of the inner membrane and provide increased
surface area for chemical reactions, which take place in
mitochondria [14].
M i t o c h o n d r i a lb i o g e n e s i si sap r o c e s st h a ti n v o l v e si n t e r -
action between the genetic systems of the organelle and the
nucleus.Duringthisprocess,mitochondriaarenewlyformed
in the cell. Many diﬀerent signals can activate mitochondrial
biogenesis. The main regulators of mitochondrial biogen-
esis include the peroxisome proliferator-activated receptor
gamma coactivator (PGC) family of transcriptional activa-
tors, which consists of PGC-1α,P G C - 1 β,a n dP G C - r e l a t e d
coactivator (PRC) [15]. PGC-1α plays a role in the activa-
tion of nuclear respiratory factor 2 and together they co-
activate nuclear respiratory factor 1. Consequently, nuclear
respiratory factor 1 activates Tfam, which is important for
mitochondrial DNA (mtDNA) transcription, translation,
and repair. Thus, PGC-1 family coactivators act as mediators
between the environment and the transcriptional machinery
regulating the biogenesis of mitochondria [16].
Mitochondria also have roles in signaling, cellular dif-
ferentiation, cell growth and cell death [17]. Dysfunction
of the mitochondria is implicated in primary mitochondrial
disorders, cardiac dysfunction, and the aging process. As one
of the main sources of reactive oxygen species (ROS), these
organelles can themselves be aﬀected by oxidative damage,
potentially membrane permeability transition, aﬀecting the
aging process and disease pathogenesis [18]. Oxidative dam-
age to mitochondrial macromolecules can also transform
into an apoptosis mechanism, which is the process of pro-
grammed cell death. Thus, many apoptotic responses occur
in mitochondria which are altered in electron transport,
the loss of membrane potential,t h ec h a n g e si no x i d a t i o n -
reduction potential, the release of caspase regulators, and the
attendance of pro- and anti-apoptotic Bcl-2 family proteins.
Therefore, it is plausible that the eﬀects of mitochondrial
disruptions can play a role in human aging processes
and degenerative diseases such as PD [19]. Sometimes,
mitochondria containing a mutated genome are removed
from the cell by mitophagy, a term for autophagy of the
mitochondria [20].
3.Mitochondrial Dysfunction in
Parkinson’s Disease
The combination of mitochondrial dysfunction and
increased oxidative stress are assumed to assist in the
pathogenesis of PD [21]. Many lines of evidence suggest
that mitochondrial dysfunction plays a central role in the
pathogenesis of PD. The ﬁrst observation in the early 1980s
was that an inhibitor of complex I of the electron transport
chain can induce parkinsonism. Moreover, mitochondria are
targeted for the actions of parkinsonian neurotoxins such
as 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP),
and its metabolite 1-methyl-4-phenylpyridinium (MPP+),
6-hydroxydopamine (6-OHDA), rotenone, and paraquat
[22, 23].
Deﬁciency in mitochondrial respiratory chain complex
I and cristae disruption have been consistently described in
PD [24]. It has been known that mitochondrial respiratory
complexI(NADH-quinoneoxidoreductase)activitydeclines
in the SNpc of PD patients [25, 26]. Moreover, the ﬁrst
transgenic mouse model for complex I deﬁciency has
recently been generated. However, in this model, ATP levels
were at the normal level, and oxygen consumption was not
aﬀected in NADH:ubiquinone oxidoreductase iron-sulfur
protein 4 (NDUFS4) knocked-out mice. Furthermore, ROS
formation in the neuronal cultures derived from those mice
did not increase as was expected. It is clear that more in vivoParkinson’s Disease 3
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Figure 1: The role of the Nrf2 pathway in PD pathogenesis. In the case of oxidative damage, mitochondria produce increased amounts of
ROS. Then, ROS activate Nrf2 bound to Keap1 in the cytoplasm, and it translocates into the nucleus to transactivate the transcription of
ARE-bearing genes, which in turn activates the antioxidant defense system and mitochondrial biogenesis. In this pathway, PD-related genes
are also involved. DJ-1 is found to inhibit oxidative damage in mitochondria. Another PD-related gene is PINK, which prevents impaired
membrane potential of mitochondria and prevents apoptosis by counteracting cytochrome c release that leads to apoptosis of nigral cells.
Lastly, Parkin was found to inhibit cytochrome c release that leads to caspase activation and apoptosis of nigral cells. Ubiquitin-interacting
p62 also has a role in Nrf2 activation. It normally plays a role in transportation of ubiquitinated proteins to autophagosome.p62 was found
to be interacting with Keap1 and transports it for autophagic degradation and provides indirect activation of Nrf2. p62 also has ARE in its
promoter region which creates a positive feedback loop between Nrf2 and p62.
models are needed in order to explain the role of complex I
deﬁciency in PD [27].
As in vivo evidence of mitochondrial dysfunction in
PD, Hattingen et al. used a combination of anatomical
magnetic resonance imaging and phosphorus and proton
magnetic resonance spectroscopic imaging. They reported
the presence of mitochondrial dysfunction of nigrostriatal
dopaminergic neurons (see Figure 1). They also suggested
that mitochondrial dysfunction phenomenon occurs in the
early stages of PD pathogenesis [28].
mtDNA has an increased susceptibility to mutations
because of less eﬃcient DNA-repair mechanisms and the
absence of protective histones. There are several clinical
studies indicating a link between PD and speciﬁc mtDNA
point mutations [29]. There is also a link between mtDNA
and neurodegeneration,which was veriﬁed by geneticmouse
models. Mitochondrial transcription factor A (Tfam) is
a gene encoding the Tfam protein, which plays a role
in promoters within the D-loop region of mtDNA and
provides regulation of the transcription and replication [30].
Both nuclear respiratory factor 1 and nuclear respiratory
factor 2 can adjust the expression of the Tfam gene by
attaching to consensus-binding sites. When a conditional
Tfam knockout mouse in midbrain dopaminergic neurons
was generated, decreased mtDNA expression, respiratory
chain deﬁciency,and neuronalcell deathleading to staggered
L-dopa-responsive impairment of motor functions were
observed [31].
Remarkably, recent studies indicate that several PD-
associated genes, directly or indirectly, impinge on mito-
chondrial integrity, thereby providing a speciﬁc link to
the mitochondrial dysfunction observed in sporadic PD
[3, 32]. The protein products of PD genes, including
alpha-synuclein, Parkin, PTEN-induced kinase 1 (PINK1),4 Parkinson’s Disease
DJ-1, leucine-rich repeat kinase 2 (LRRK2) and HTR2A are
localized to the mitochondria under certain conditions [33].
Functionalstudiesin animal and cellularmodelsystems have
shown that PINK1 and Parkin play important roles in main-
taining mitochondrial integrity and regulate mitochondrial
morphology[3].Loss-of-function mutationsin thegenes for
thesepr oteinsar etheprimarycauseofearly-onsetautosomal
recessive forms of PD [1]. Parkin is an E3 ubiquitin-protein
ligase, and impaired proteasome function hasbeen described
in sporadic PD. Parkin, therefore, promotes the degradation
of dysfunctional mitochondria in cell culture conditions
[34]. PINK1 represents the only kinase known to exhibit a
canonical N-terminal mitochondrial localization signal [35].
These proteins are involved in mitophagy, the degradation
process of terminally dysfunctional mitochondria in the
lysosome [3, 32, 36]. Mutations in LRRK2 cause autosomal-
dominant familial PD. This kinase modulates vulnerabil-
ity to mitochondrial dysfunction induced by neurotoxins
[37]. Furthermore, DJ-1 localizes to mitochondria during
oxidative stress, where it exhibits peroxiredoxin-like activity
[38]. Mutations in DJ-1 render animals and cultured cells
moresusceptibletooxidativestress andmitochondrial toxins
implicated insporadic PD,lending support to thehypothesis
that some PD cases may be caused by gene-environmental
factor interactions [39, 40]. A small proportion of alpha-
synuclein is imported into mitochondria, where it accumu-
lates in the brains of PD patients and may impair respiratory
complex I activity [41]. Alpha-synuclein binds to mitochon-
dria and leads to mitochondrial fragmentation [42].
4.TheNrf2/AREPathway
In pathology of neurodegenerative disorders, the generation
ofROSmay be harmful aﬀecting proteins, lipids, and nucleic
acids [45]. ROS itself regulates redox homeostasis activating
a group of genes and signal transduction pathways [46].
T h eN r f 2p a t h w a yi so n eo ft h ep a t h w a y st h a tr e s p o n dt o
ROS by activating the transcription of phase II detoxiﬁcation
enzymes [47]. It was ﬁrst identiﬁed by Moi et al. in 1994, as
controlling the expression of β-globin gene [47]. It belongs
to the cap and collar family of transcription factors having
a distinct basic leucine-zipper motif [48]. Nrf2 is found in
the cytosol bound to its inhibitor kelch-like ECH-associated
protein (Keap1). When redox balance is tipped toward the
oxidative side, Nrf2 translocates into the nucleus and acti-
vatesthetranscriptionofARE-containinggenes[49].During
this activation, Keap1, which is sensitive to electrophilic
and oxidative stimuli, regulates Nrf2 modiﬁcation, holding
Nrf2 in the cytosol along with actin ﬁlaments [50]. Unless
it is activated, Nrf2 is ubiquitinated by the E3-ubiquitin
ligase-like domain of Keap1, followed by 26S proteasomal
degradation[50].Therefore,Keap1regulatesNrf2negatively,
by promoting its sequestration and degradation.
Nrf2 is regulated by interactions between the conserved
motifs DLG and ETGE within the Neh2 domain of Nrf2,
the domain which regulates cellular stress responses, and
the DGR region on Keap1. All of these domains provide
correct positioning of Nrf2 for ubiquitination. When ROS
accumulation increases in the cell, the binding to the DLG
motif weakens; thus, ubiquitination is prevented [51–53].
In this way, degradation of Nrf2 decreases and stability
of Nrf2 increases [43]. Extracellular signal-regulated kinase
(ERK), c-Jun N-terminal protein kinase (JNK), and p38
mitogen-activated protein kinase (MAPK) pathways were
shown to regulate Nrf2 transcriptional activity with an
unknown mechanism. ERK and JNK appear to regulate
positively the Nrf2 pathway after ARE-inducing substances,
whereas p38 MAPK was reported to regulate Nrf2 both
positively and negatively [43, 54]. ERK,JNK, and p38 MAPK
act by phosphorylating N-terminal serine residues on Nrf2,
which results as a response to electrophiles and oxidative
stress [55]. Moreover, one of main signaling pathways,
cytoprotective phosphotidylinositol-3 kinase (PI3K), which
regulates maintenance of cellular homeostasis, was shown
to regulate hemeoxygenase-1 (HO-1) under inﬂammatory
stress [56]. Thus, it is proposed that the PI3K/Akt signaling
pathway acts upstream of Nrf2 signaling. There are diﬀerent
upstream mechanisms, other than MAPK and PI3K/Akt,
which are pancreatic endoplasmic reticulum kinase (PERK)
and protein kinase C (PKC). In the case of redox imbalance,
ROS can induce endoplasmic reticulum (ER) stress resulting
in improper folding of proteins. There are diﬀerent mecha-
nisms to deal with this, one of which is PERK. Cullinan et
al. found that Nrf2-target genes are activated in ER stress
proposing PERK as the activator of Nrf2 [57]. Another Nrf2
mediator is PKC, which was ﬁrst found by Huang et al. in
2000. As a result of inhibition experiments, they proposed
that PKC is an upstream activator of Nrf2 signaling [58].
There are two hypotheses to explain the mechanism of
Nrf2 translocation into the nucleus. According to the ﬁrst
hypothesis, there is nuclear localization signal in its basic
region and two nuclear export signals in its leucine zipper
and transactivation domain in order to provide Nrf2 nuclear
translocation. In normal conditions, the nuclear localization
signal is balanced by the nuclear export signal, and the
sequestrationofNrf2occursinthecytosol.However,instress
conditions, the redox sensitive nuclear export signal found
in the transactivation domain is disrupted. Thus, the nuclear
localization signal drives translocation into the nucleus [59,
60]. However, this hypothesis fails to explain constitutive
transcription of drug-metabolizing enzymes under normal
conditions. For this reason, an alternative hypothesis was
proposed. In this second hypothesis, Nrf2 is constitutively
expressed and translocates into the nucleus. Its regulator
and Keap1 enter into the nucleus by the CRM1/exportin
pathway for removal and degradation of Nrf2, and after
degradation it gets back into the cytosol. Consequently,
under oxidative stress conditions, Nrf2 is expressed at the
normal rate; however, its degradation rate decreases. In this
way, its nuclear accumulation and transcriptional activity
are enhanced [61, 62]. In addition to the above hypotheses,
a novel ubiquitin-binding protein, p62 (sequestosome 1,
SQSTM1), was recently shown to activate Nrf2. Studies
suggest that p62 interacts with the Keap1-binding site of
Nrf2, resulting in activation and triggering of downstream
events of the Nrf2 pathway [63, 64].
In cells, there are mechanisms to deal with oxidative
stress, including phase II detoxiﬁcation enzymes, whichParkinson’s Disease 5
Table 1: Nrf2 target genes.
Group Gene symbol Gene name Function
GSH γ-glutamyl-cysteinyl-glycine
Maintains redox
homeostasisduring
oxidative stress
GST Glutathione-S-transferase Cellular detoxiﬁcation
Gcl Glutamate cysteine ligase Catalyzes glutathione
synthesis
Glutathione homeostasis Gcs Glutamate cysteine synthetase Catalyzes glutathione
synthesis
GS Glutathione synthetase Catalyzes glutathione
synthesis
GPx Glutathione Peroxidase
Catalyzes reduction of
H2O2 or organic
hyperoxides to water
GR Glutathione Reductase Catalyzes reduction of
oxidized GSSH to GSH
NQO-1 NAD(P)H quinone
oxidoreductase-1
Catalyzes two-electron
reduction of quinones
Drug metabolism Ugt UDP-glucuronosyltransferases
Catalyzes endogenous and
exogenous substances with
glucuronic acid
mEH Microsomal epoxide hydrolase
Inactivates epoxides
converting to vicinal
dihydrodiol
Stress response proteins/iron
metabolism
Ferritin Ferritin Iron binding protein having
role in iron oxidative stress
HO-1 Heme oxygenase-1 Catalyzes oxidative cleavage
of Fe-protoporphyrin-IX
Excretion/transporter
Mdr Multi-drug resistance protein Drug eﬄux pump for
xenobiotic compounds
Mrp Multidrug resistance
associated protein
Multispeciﬁc organic anion
transporter
G6PDH Glucose-6-phosphate
dehydrogenasea Glycolysis
Other genes metabolism Taldo Transaldolasea Pentose phosphate pathway
enzyme
Tkt Transketolasea
Channeling of excess
glucose phosphates to
glycolysis
Pafah PAF acetylhydrolasea
Catalyzes the degradation
of platelet-activating factor
to biologically inactive
products
Immune system Ptgs2 Prostaglandin-endoperoxide
synthase 2a Prostaglandin biosynthesis
Dig Dithiolethione-inducible
genea
Inhibition of chemically
induced tumorigenesis
Tac2 Tachykinin 2a Peptide neurotransmitter
Calb1 Calbindin-28Kb Calcium binding protein
Calcium homeostasis Syt1 Synaptotagmin-1b Synaptic transmission
Hpca Hippocalcinb Calcium binding protein
S100A1 S100 calcium binding protein
A1b Calcium binding protein6 Parkinson’s Disease
Table 1: Continued.
Group Gene symbol Gene name Function
Ngfg Nerve growth factor-γb Growth factor for neuron
survival
Growth factor FGF-13 Fibroblast growth factor-13b Nervous system
development and function
FGF-14 Fibroblast growth factor-14b Nervous system
development and function
BDNF Brain-derived neurotrophic
factorb
Growth factor for neuron
survival
nGEF Neuronal GEFb Intracellular signaling
networks
Prkcb Protein Kinase C-βb Signaltransduction
Intracellular signaling Gng3 G-protein-γ3b Signaltransduction
Adm Adrenomedullinb Adrenal development
Crh Corticotropin-releasing
hormoneb
Hormone released in
response to stress
Neurotransmission/channel
Clcn Chloride channelb Ion channel protein
Gabr1 GABA-A receptor-1b Neurotransmitter receptor
Gabrg3 GABA-A receptor, gamma 3b Neurotransmitter receptor
Gabbr1 GABA-B receptor-1b Neurotransmitter receptor
Nrf2 activates a battery of ARE-driven genes, also known as classic Nrf2-target genes, which are classiﬁed into 4 groups as glutathione homeostasis, drug
metabolism,stress-response protein/iron metabolism,and excretion/transporter [43]. In addition to classicgenes, microarray experimentsrevealed cell-type
speciﬁc target genes. From (a) primary astrocyte and (b) primary neuronal cultures,novel targets were identiﬁed [44]. They also are stated as other genes.
have ARE in its promoter or enhancer regions. According
to genetic analyses, the ARE sequence is found in many
genes, which play important roles in gene regulation [65,
66]. Nrf2 also interacts with the AP-1 family proteins
Jun, Fos, and Maf. Maf binds to the maf recognition
element (MARE), which is very similar to the core sequence
of ARE [67–70]. However, maf proteins are reported to
regulateARE-containinggenesnegatively[69].Furthermore,
some maf genes, MafF, and MafG modulate the expression
of ARE-containing genes [48]. Overexpression studies on
Jun revealed that Jun acts as a positive regulator of the
transcription of ARE-regulated genes. Moreover, according
tothestudieswhichunraveltherelationshipbetweenFosand
Jun, itwasconcludedthatFosactsasnegative regulator,in an
opposite fashion to Jun [71].
Genes transcribed after Nrf2 activation are called the
“Nrf2 regulon.” This regulon performs several cellular func-
tions, such as drugmetabolism, ROS scavenging,glutathione
homeostasis, eﬄux transport pathways, and activation of
stress response proteins, which are vital for redox homeosta-
sis [61, 72]. In the last decade, the role of Nrf2 in disease
pathogenesis and toxic insults was shown to be protective,
and it is conﬁrmed to be a multiorgan protector [44]. The
Nrf2 regulon genes can be classiﬁed into various classes
based on their functions: glutathione homeostasis, drug
metabolism, stress-response protein or iron metabolism and
excretion/transporter. The functions of each gene group and
genesaresummarizedinTable 1.Insomestudies,microarray
analysis of the Nrf2 regulon revealed more genes than classi-
cal ARE-containing genes by comparing expression patterns
ofneurons and astrocytes, which are indicated as other genes
in Table 1 [44]. In addition to the genes listed in Table 1,
we performed in silico transcription factor binding analysis
using the JASPAR database by searching for ARE sequence
in the promoter [73]. Novel Nrf2 targets were obtained,
such as nuclear respiratory factor-1, Tfam, and peroxisome
proliferator-activated receptor gamma coactivator 1 alpha
(PGC1A). Nuclear respiratory factor-1 was experimentally
validated to be a target gene for Nrf2 activation, which
leads to mitochondrial biogenesis. In this way, apoptosis
and necrosis can be prevented [74]. Peroxisome proliferator-
activated receptor gamma (PPAR-γ)i sap r o t e i nt h a th a s
many beneﬁcial eﬀects including anti-inﬂammation in mul-
tiple tissues. Cho et al. ﬁrst showed the regulation of PPAP-γ
by Nrf2. They showed antioxidant eﬀects of both Nrf2 and
PPAR-γ, and they suggested that a PPAR-γ agonist can be
used to combat oxidative damage [75].
5.TheNrf2/AREPathwayand
Parkinson’s Disease
Several lines of evidence suggest the involvement of the
Nrf2/ARE pathway in the pathogenesis of PD. The ﬁrst
evidence came from a postmortem study that examined the
expression and localization of Nrf2 in susceptible neuron
populations in AD and PD brain tissues [76]. Ramsey et al.
showed that in neurodegenerative diseases, Nrf2 expression
is altered in both neurons and astrocytes. As compared with
age-matched normal controls, nuclear Nrf2 staining was
decreased in hippocampal CA1 neurons and surrounding
glia in AD brains, whereas nuclear localization of Nrf2 was
induced in SN in PD brains, even though the responseParkinson’s Disease 7
appeared insuﬃcient to protect neurons from degeneration.
Consistent with the ﬁndings of the study by Ramsay et al.,
increased glutathione was found in PD patients, probably
reﬂectingaresponse tooxidativedamage[77].Anotherstudy
by Spencer et al. found decreased glutathione levels [78].
Since Nrf2 regulates several enzymes involved in glutathione
synthesis, increased Nrf2 in surviving PD nigral neurons
could be interpreted as an appropriate neuronal response
to oxidative stimuli, even though the response appears
insuﬃcient to protect neurons from neurodegeneration.
Similarly, in the MPTP model of PD, ARE-dependent gene
expression was decreased in striatum whereas it increased
in SN [79]. Because subcellular traﬃcking is critical to the
activity of the Nrf2/ARE pathway, Ramsey et al. concluded
that disrupted or insuﬃcient ARE responses likely occur
downstream of Nrf2 nuclear localization in PD [76]. Addi-
tional downstream mechanisms may interfere with ARE
transactivation despite nuclear stabilization of Nrf2. Further
investigation is needed to understand why Nrf2 nuclear
translocation is not suﬃcient to prevent oxidative stress
or ongoing neurodegeneration in SN. Ramsey et al. did
not report increased nuclear Nrf2 staining in surrounding
glia in SN in postmortem brains from PD individuals and
questioned the necessity of astroglial Nrf2 activation in
neuroprotection. In reduced in vitro cell culture systems,
increased neuronal Nrf2 activation protects neurons from
the oxidative insult induced by parkinsonian neurotoxins
such as paraquat, 6-OHDA, MPP+, and rotenone even in the
absence of astroglia [80–88].
Primary cell culture systems used in these studies
typically utilize either neuronal cell lines or dissociated
cells. Nevertheless, it is likely that increased Nrf2 activity
in both neurons and glia contributes to neuronal survival
in disease states. The glia-enriched and mixed neuron-
glia culture studies by Shih et al. suggest that in vitro
neuroprotection against glutamate toxicity is not limited to
increased neuronal Nrf2 activation, because activation of
glial Nrf2 system also protects cultured neurons from insult
[89]. A microarray analysis used to evaluate potential glial
versus neuron-speciﬁc contributions to the neuroprotective
eﬀects of ARE activation and Nrf2 dependence showed that
Nrf2 induction activates the expression of diﬀerent genes
in cultured astrocytes as compared with cultured cortical
neurons. These results suggest that Nrf2-dependent genetic
changes alter neuron-glia interactions resulting in neuro-
protection [90]. The unique combination of cells found
within organotypic nigrostriatal cocultures provides an ideal
system by which we can examine this relationship between
neurons and glia [91]. The neuroprotective eﬀects of in vitro
Nrf2 activation were also demonstrated in such organotypic
nigrostriatal cocultures although the astroglial component
was not studied [91]. All neurodegenerative diseases have
diﬀerent causes and mechanisms including progression, age
of onset quality and severity of symptoms, survival after
onset and cell population aﬀected. Nrf2 was found to
be regulated diﬀerently in neurons versus astrocytes [90].
Therefore, Ramsey et al. proposed that Nrf2 might regulate
diﬀerent gene products in various neuronal subpopulations
(i.e., hippocampal neurons versus nigral neurons) [76].
Further studies are needed to explore how Nrf2 localization
is regulated in a cell-type-speciﬁc manner, how it diﬀers in
various cellular populations and neuronal subpopulations,
and how these diﬀerences may contribute to neuronal
protection.
Thelink betweentheNrf2/AREpathwayandPD was also
studied using in vivo neurotoxin-based animal models of PD
[84, 92]. Nrf2 knockout mice display increased vulnerability
to 6-OHDA, and the induction of the Nrf2/ARE pathway by
transplantation of astrocytes overexpressing Nrf2 can protect
against 6-OHDA-induced damage in mouse brain [84].
GeneticdeﬁciencyofNrf2increasesMPTPsensitivityinmice
[79]. Furthermore, Nrf2 expression restricted to astrocytes is
suﬃcient to protect against MPTP in transgenic mice with
Nrf2 under control of the astrocyte-speciﬁc promoter for
the glial ﬁbrillary acidic protein (GFAP)-Nrf2. These results
show that astroglial modulation of the Nrf2/ARE pathway
alsoplaysapivotalroleinneuroprotectioninvivo.According
to the results of a very recent study based on the MPTP
model, Nrf2 also modulates toxin-mediated activation of
microglia, another glial cell type in the CNS [93]. Dopamin-
ergic neurodegeneration and microglial activation induced
by chronic injection of MPTP were more severe in Nrf2
knockout mice than in wild-type mice. Characteristic of
classical microglial activation, the levels of proinﬂammatory
cytokines interleukin-6 (IL-6) and tumor necrosis factor-
alpha (TNF-α) and the enzymes inducible nitric oxide syn-
thase (iNOS)and cyclooxygenase-2(COX-2)were increased,
while anti-inﬂammatory markers attributable to alternative
microglial activation were decreased [94]. These results
demonstrate a crucial role of Nrf2 in the modulation of
microglial dynamics [93]. There may be crosstalk between
glial cell subpopulations characterized by the modulation
of the activation status of microglia by astroglia [95].
The astrocytes, the most abundant cells in the brain, can
secrete one or more factors capable of modulating microglial
activation by regulating microglial Nrf2 activation. Treat-
ment of microglia with astrocyte culture-conditioned media
induces the nuclear translocation of Nrf2 and enhanced
HO-1 promoter activity in an ARE-dependent manner and
increases the expression and activity of HO-1 in microglia.
Furthermore, treatment with astrocyte culture-conditioned
media suppresses Interferon-gamma- (IFN-γ-)induced ROS
production, leading to reduced iNOS expression and nitric
oxide (NO) release [95]. However, as demonstrated by a
very recent in vivo study, HO-1 may not be involved in the
neuroprotection elicited by Nrf2 in experimental parkinson-
ism [92]. Deﬁciency of HO-1 does not protect or enhance
s e n s i t i v i t yt on e u r o n a ld e a t h ,w h e r e a sN r f 2 - k n o c k o u tm i c e
showed exacerbated gliosis and dopaminergic nigrostriatal
degeneration in the MPTP model of PD [96, 97].
Genetic evidence indicating a link between Nrf2/ARE
pathway and PD came from a recent study in which a
complete haplotype analysis of the NFE2L2 and Keap1
genes in relation to the risk of PD was performed in
two independent case-control materials [98]. A protective
NFE2L2haplotype was found in both European case-control
materials. The molecular consequence of this haplotype may
be increased eﬃciency in the Keap1-Nrf2-ARE response to8 Parkinson’s Disease
oxidative stress and thereby higher capacity to withstand
endogenous or environmental risk factors for PD. Genetic
variation in Keap1 did not show any associations. These
results together with recent preclinical data provide another
link between oxidative stress and the pathogenesis of PD and
support NFE2L2 as a novel susceptibility gene for PD [98].
The interaction of Nrf2 with a parkinsonian gene, DJ-1
(PARK7), may provide another link between Nrf2 function
and PD. A recently discovered function of DJ-1 is to stabilize
Nrf2bypreventingitsinteractionwithKeap1andNrf2’ssub-
sequent ubiquitination [99]. Furthermore, protein expres-
sion of Nrf2 signiﬁcantly decreases in paraquat-treated DJ-
1-deﬁcient mice [100]. However, the ﬁndings of the study by
Gan et al. using primary mouse embryonic ﬁbroblasts were
not conﬁrmed in primary cortical neuronal and astrocyte
cultures in vitro and ARE-driven human placental alkaline
phosphatase (hPAP; ARE-hPAP) transgenic reporter mice in
vivo [101]. Nrf2 activation, Nrf2-dependent gene induction,
and Nrf2-mediated neuroprotection do not appear to be
dependent on the presence of DJ-1 in the brain or in
primary cultures derived from the brain. The most probable
explanation for this discrepancy is the diﬀerent cell types
used in the two studies, suggesting that the relationship
between DJ-1 and Nrf2 is cell-type speciﬁc. Neuroprotection
by DJ-1 was conﬁrmed in the second study [101].
StudiesexaminingtheNrf2-activating eﬀectsofPDdrugs
support the link between the Nrf2/ARE pathway and PD.
Apomorphine (Apo) is a drug used for clinical therapy of
PD. It is a dopamine D(1)/D(2) receptor agonist and has
scavenger and protective eﬀects in ROS-induced cell death.
Hara et al. reported that Apo enhances protection in 6-
OHDA in vitro PD model in SH-SY5Y neuroblastoma cells.
In that study, the involvement of the Nrf2 pathway in Apo-
enhanced protection was also investigated. They observed
nuclear translocation of Nrf2 into the nucleus and induced
the expression of HO-1 gene in a dose-dependent fashion.
On the other hand, cotreatment of Apo with antioxidant N-
acetylcysteine suppressed the induction of HO-1 expression.
Thus,ApoactsbyproducingintracellularROSandactivating
the Nrf2 pathway to promote neuroprotective eﬀects [81].
In addition to Apo, there is another cytoprotective drug,
Deprenyl (Selegiline), that is, a promising candidate for
neuroprotection, but its mode of action was unknown.
However, Nakaso et al. reported a novel mechanism for the
mode of action of Deprenyl, which involves PI3K and Nrf2
downstream oxidative-stress-related proteins. It increased
the expression levels of HO-1, PrxI, TrxI, TrxRxI, gamma-
GCS, and p62/A170, induced Nrf2 nuclear accumulation,
and increased the strength of Nrf2 binding to ARE site. Nrf2
activation led to the induction of PI3K-controlled antioxi-
dant molecules, and TrkB was identiﬁed as the upstream ele-
ment of the PI3K/Nrf2 mechanism. Thus, protective eﬀects
ofDeprenyldependonPI3K-Nrf2activation, which switches
the antioxidant mechanism leading to cytoprotection [63].
The latest clinically used PD drug is bromocriptine, which
is a dopamine agonist. Not only does it normally improve
motor deﬁcits by dopamine D2 receptor activation, but
it also has neuroprotective and antioxidant activities. As
reported by Lim et al., bromocriptine upregulates NAD(P)H
quinone oxidoreductase-1 (NQO1) expression and increases
its activity, thus leading to the protection of PC12 rat
adrenal pheochromocytoma cells against oxidative damage.
Bromocriptine also increased Nrf2 expression and nuclear
translocation. It is known that bromocriptine leads to
cytoprotection and antioxidant eﬀects via the PI3K/Akt
pathway, but independent from dopamine receptor acti-
vation. Also, dopamine receptor D2 antagonist does not
aﬀect the cytoprotective eﬀect of bromocriptine and Nrf2-
ARE activation by bromocriptine in dopamine D2 receptor
expressing and nonexpressing cells. Consequently, NQO1 is
a novel therapeutic target for PD, which can be upregulated
by PI3K and Nrf2 activation [102].
Speciﬁc links between Nrf2 function and PD have been
revealed.TheactivityofNrf2decreaseswithaging[103,104],
the major risk factor for the developmentand progression of
PD [105]. Dysregulation of the Nrf2/ARE pathway is seen in
PD.Nrf2 activators includingknown antiparkinsonian drugs
(deprenyl and apomorphine [63, 81]) protect dopaminergic
neurons against parkinsonian neurotoxins both in vitro
and in vivo. Deﬁciency of Nrf2 aggravates experimental
parkinsonism. Finally, apart from the stringent link between
the Nrf2/ARE pathway and pathophysiological processes
involved in PD such as oxidative stress, neuroinﬂammation,
and ER stress, Nrf2 has the potential to interact with several
molecules implicated in mitochondrial biogenesis (nuclear
respiratory factors, PGC-1α,T f a m )a n dp 6 2w h i c hp l a y s
a role in mitophagy and the ubiquitin proteasome system
(UPS) implicated in the pathogenesis of PD.
6.Nrf2/AREPathwayActivationasa Novel
TherapeuticApproachto Mitochondrial
Dysfunction in Parkinson’s Disease
As evidenced from postmortem tissue analyses and genetic
analyses in humans and pathological studies in animal
models, mitochondrial dysfunction plays a major role in
PD, which leads to oxidative stress, DNA damage, and
altered mitochondrial morphology and physiology. There-
fore, therapeutic agents targeted to the mitochondria are
thought to be promising tools for PD patients, such as
agents targeting energy metabolism, mitochondria-targeted
antioxidants, and more promising drugs that target the
ARE/Nrf2/Keap1 pathway.
The Nrf2 pathway plays a role in redox homeostasis in
cells.ThemainfunctionsofNrf2 weredescribedintheprevi-
o u sp a r to ft h i sp a p e r .T h eN r f 2p a t h w a yi sa c t i v a t e db yR O S
accumulationincells; however,fortherapueticpurposes,itis
found to be activated by synthetic triterpenoids (TP), which
are analogs of olenolic acid. They function as inhibitors of
oxidativestress andcellularinﬂammatory processes andwere
showntobepr otectiveincancermodels[106].Moreover,the
use of dietary compounds, synthetic chemicals, and xenobi-
otics decreases the incidence of diseases. For many decades,
chemical substances from plants, called phytochemicals,
have been shown to have chemopreventive activities, and
most of them are suggested as Nrf2 inducers [107]. The
potent chemopreventive compounds that induce Nrf2 canParkinson’s Disease 9
be listed as sulforaphane from cruciferous vegetables [108],
curcumin [109], epigallocatechin-3-gallate from green tea
[110], resveratrol from grape [111], caﬀeic acid phenethyl
ester [109], wasabi [112], cafestol, kahweol [113], cinnamon
basedcompounds[114],zerumbone[115],garlicorganosul-
fur compounds [116], lycopene [117], carnosol [118], and
avicins [119]. Novel compounds have been continuously
discovered.
TPs are a group of Nrf2-activating compounds. Recently,
novel Nrf2-activating, synthetic TP, CDDO methylamide
(CDDO-MA), was tested by Yang et al. for neuroprotective
eﬀectsin 3-nitropropionicacid (3-NP)ratand MPTP mouse
models. CDDO-MA showed signiﬁcant protection against
both models and tert-butylhydroxyperoxide-induced ROS
degeneration[120]. Inadditionto protectiveeﬀects, CDDO-
MA upregulated the expression of genes involved in mito-
chondria biogenesis, glutathione synthesis, and antioxidant
mechanisms. Thus, this compound was thought to be useful
for the treatment of neurodegenerative diseases.
Other neuroprotective agents that induce the expression
of hemeoxygenase-1 are electrophilic neurite outgrowth-
promoting prostaglandin (NEPP) compounds [121]. NEPP
compounds are cyclopentenone prostaglandin derivatives
and function as neurotrophic factors. According to a report
by Satoh et al., NEPPs were preferentially taken up into neu-
rons, where they bind to Keap1 in a thiol-dependent fashion.
They showed that NEPPs are neuroprotective in a glutamate
e x c i t o t o x i c i t ym o d e li nv i t r oa n di nas t r o k em o d e li nv i v o .
They suggest that NEPPs activate the Keap1/Nrf2 pathway
to modulate the prevention of excitotoxicity; therefore, they
can be used as therapeutics in stroke and neurodegenerative
diseases [122].
Shih et al. showed that dietary administration of Nrf2
inducer (tert-Butylhydroxyquinone) reduced susceptibility
to 3-NP and increased striatal and cortical gamma-glutamyl-
cysteinyl- glycine (GSH) levels in Nrf2-expressing mice but
not in Nrf2−/−. These results suggested that Nrf2 inducers
to be dietary administration may be alternative drugs for the
treatment of neurodegenerative disorders [123].
Neuroprotective agents such as erythropoietin (Epo),
which is known to pass the blood brain barrier [124], also
exert Nrf2-activating eﬀects. Epo provides neuroprotection
in MPTP- and 6-OHDA-induced toxin models of PD [125,
126]. Recently, Epo has been found to activate Nrf2 in
SH-SY5Y cells [127]. Epo induced Nrf2 translocation to
the nucleus and upregulated the expression of the HO-1
gene. Also, MAPK and PI3K inhibitors caused decreased
translocation of Nrf2 caused by Epo. These results suggest
thatEpoactivates theNrf2 pathway and thePI3Kand MAPK
pathways as well. It is interesting that Epo, which is reported
as neuroprotective in PD animal models, triggers neuronal
Nrf2 translocation. Thus, the neuroprotective eﬀects of Epo
can be mediated by Nrf2.
7.Conclusions
Mitochondrial dysfunction plays a central role in the patho-
genesis of PD. For this reason, new therapeutic strategies in
PD targeting the restoration of mitochondrial dysfunction
are being developed. The failure of antioxidant therapy
strategiesaloneinclinicaltrialshasencouragedeﬀortstoﬁnd
novel approaches strengthening endogenous antioxidant
defense systems and inducing mitochondrial biogenesis and
anti-inﬂammatory responses [123]. In this regard, Nrf2, a
master regulator of the induction of a battery of genes
aﬀecting several cytoprotective systems, may be a promising
target to counteract mitochondrial dysfunction and its
consequences in PD. Thus, exogenous Nrf2 inducers should
be tested for therapeutic potential in PD.
Abbrevation
MPTP: 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine
MPP+: 1-methyl-4-phenylpyridinium
3-NP: 3-nitropropionic acid
6-OHDA: 6-hydroxydopamine
ATP: Adenosine triphosphate
ARE: Antioxidant response element
Apo: Apomorphine
hPAP; ARE-hPAP: ARE-driven human placental
alkaline phosphatase
CDDO-MA: CDDO methylamide
JNK: c-Jun N-terminal protein kinase
COX-2: Cyclooxygenase-2
Epo: Erythropoietin
ERK: Extracellular signal-regulated kinase
GSH: Gamma-glutamiyl-cysteinyl- glycine
GFAP: Glial ﬁbrillary acidic protein
HO-1: Hemeoxygenase-1
hPAP: Human placental alkaline
phosphatase
iNOS: Inducible nitric oxide synthase
IFN-γ: Interferon-gamma
IL-6: Interleukin-6
Keap1: Kelch-like ECH-associated protein
LRRK2: Leucine-rich repeat kinase 2
MARE: Maf recognition element
mtDNA: Mitochondrial DNA
MAPK: Mitogen-activated protein kinase
Tfam: Mitochondrial transcription factor A
NDUFS4 gene: NADH:ubiquinoneoxidoreductase
iron-sulfur protein 4
NADPH: Nicotinamide adenine dinucleotide
phosphate
NQO1: NAD(P)H quinone
oxidoreductase-1
NEPP: Neurite outgrowth-promoting
prostaglandin
NO: Nitric oxide
Nrf2: Nuclear factor E2-related factor 2
OXPHOS: Oxidative phosphorylation
PD: Parkinson’s disease
PPAR-γ: Peroxisome proliferator-activated
receptor gamma
PGC: Peroxisome proliferator-activated
receptor gamma coactivator10 Parkinson’s Disease
PGC1A: Peroxisome proliferator-activated
receptor gamma coactivator 1 alpha
PRC: PGC-related coactivator
PINK1: PTEN-induced kinase 1
ROS: Reactive oxygen species
SQSTM1: Sequestosome 1
SN: Substantia nigra
Snpc: Substantia nigra pars compacta
TP: Triterpenoids
TNF-α: Tumor necrosis factor-alpha
UPS: Ubiquitinproteasome system.
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